tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chad Messer, 155 are a BUY (98.73%), 1 are a HOLD (0.64%), 1 are a SELL (0.64%).
Analyst Chad Messer, carries an average stock price target met ratio of 48.58% that have a potential upside of 58.4% achieved within 263 days. Previously, Chad Messer worked at NEEDHAM.
Chad Messer’s has documented 285 price targets and ratings displayed on 27 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on IMNM, Immunome at 16-Dec-2025.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $47 was fulfilled within 5 days with a profit of $14.55 (44.84%) receiving and performance score of 89.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 24-Feb-2025
$65
$37.14 (133.31%)
$48
1 months 10 days ago
(12-Feb-2026)
0/4 (0%)
$36.93 (131.56%)
Hold Since 01-Dec-2022
$25
$-2.86 (-10.27%)
$20
2 months 16 days ago
(06-Jan-2026)
5/7 (71.43%)
$-2.47 (-8.99%)
181
Buy Since 20-Nov-2025
$40
$12.14 (43.58%)
$34
2 months 24 days ago
(26-Dec-2025)
11/16 (68.75%)
$11.98 (42.76%)
205
Buy Since 24-Nov-2025
$38
$10.14 (36.40%)
$32
2 months 26 days ago
(24-Dec-2025)
6/9 (66.67%)
$8.83 (30.27%)
71
Buy Since 03-Dec-2021
$34
$6.14 (22.04%)
$32
2 months 26 days ago
(24-Dec-2025)
6/14 (42.86%)
$4.83 (16.56%)
477
Which stock is Chad Messer is most bullish on?
What Year was the first public recommendation made by Chad Messer?
